Replies to post #107470 on Biotech Values

[DewDiligence]

…MAXY stands to reap another $65-123M…for the pharmaceutical application of the technology if Astellas buys out the Perseid joint venture that holds the molecular breeding license for therapeutics.

Why would Astellas do that? I’m seriously asking, not being rhetorical.